# Sorafenib and LBH589 in Hepatocellular Carcinoma (HCC)

> **NCT00823290** · PHASE1 · TERMINATED · sponsor: **University of Erlangen-Nürnberg Medical School** · enrollment: 2 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Sorafenib + LBH589

## Key facts

- **NCT ID:** NCT00823290
- **Lead sponsor:** University of Erlangen-Nürnberg Medical School
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-01
- **Primary completion:** 2010-12
- **Final completion:** 2010-12
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Investigator left site
- **Last updated:** 2020-12-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00823290

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00823290, "Sorafenib and LBH589 in Hepatocellular Carcinoma (HCC)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00823290. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*